How Can Nanoparticles Be Used to Overcome The Challenges of Glaucoma Treatment?

Abstract

NanomedicineVol. 9, No. 9 EditorialHow can nanoparticles be used to overcome the challenges of glaucoma treatment?Subbu Venkatraman & Tina WongSubbu VenkatramanAuthor for correspondence: E-mail Address: assubbu@ntu.edu.sgSchool of Materials Science & Engineering, NTU & Ocular Therapeutic Engineering Centre, NTU, 50 Nanyang Avenue, 639798 Singapore Search for more papers by this author & Tina WongSingapore National Eye Centre & Ocular Therapeutic Engineering Centre, NTU, 50 Nanyang Avenue, 639798 SingaporeSearch for more papers by this authorPublished Online:10 Sep 2014https://doi.org/10.2217/nnm.14.85AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: back-of-the-eye diseasesglaucomananocarriers in the eyeopacitysustained releaseReferences1 Quigley AH, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 90, 262–267 (2006).Crossref, Medline, CAS, Google Scholar2 Tan YF, Mundargi RC, Chen MHA et al. Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing. Small 10(9), 1790–1798 (2014).Crossref, Medline, CAS, Google Scholar3 Ciolino JB, Stefanescu CF, Ross AE et al. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials 35, 432–439 (2014).Crossref, Medline, CAS, Google Scholar4 Chong RS, Su DH, Tsai A et al. Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma. J. Glaucoma. 22(3), 190–194 (2013).Crossref, Medline, Google Scholar5 Jayaganesh NV, Darwitan A, Barathi VA et al. Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma. ACS Nano 8(1), 419–429 (2014).Crossref, Medline, Google Scholar6 Wong TT, Novack GD, Ho CL, Jayaganesh NV, Htoon HM, Venkatraman SS. Nanomedicine for glaucoma: sustained release latanoprost offers a new therapeutic option with substantial benefits over eye drops. Drug Deliv. Transl. Res. 4(4), 303–309 (2014).Crossref, Medline, Google Scholar7 Abrishami M, Ganavati SZ, Soroush D, Rouhbaksh M, jaafari MR, Malaekeh-Nikouei: Preparation, characterization and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina 29, 699–703 (2009).Crossref, Medline, Google Scholar8 Honda M, Asai T, Oku N, Tanaka M, Ebihara N. Liposomes and nanotechnology in drug development: focus on ocular therapies. Int. J. Nanomedicine 8, 495–504 (2013).Crossref, Medline, Google Scholar9 pSivida Corp. www.psivida.com/products-iluvien.htmlGoogle ScholarFiguresReferencesRelatedDetailsCited ByThe development of a glaucoma-specific health-related quality of life item bank supporting a novel computerized adaptive testing system in Asia11 October 2022 | Journal of Patient-Reported Outcomes, Vol. 6, No. 1Mucoadhesive and responsive nanogels as carriers for sustainable delivery of timolol for glaucoma therapyMaterials Science and Engineering: C, Vol. 118Beyond intraocular pressure: Optimizing patient-reported outcomes in glaucomaProgress in Retinal and Eye Research, Vol. 76Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments29 September 2018 | International Journal of Molecular Sciences, Vol. 19, No. 10Nanoparticles and nanofibers for topical drug deliveryJournal of Controlled Release, Vol. 240 Vol. 9, No. 9 Follow us on social media for the latest updates Metrics Downloaded 139 times History Published online 10 September 2014 Published in print July 2014 Information© Future Medicine LtdKeywordsback-of-the-eye diseasesglaucomananocarriers in the eyeopacitysustained releaseFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download